A Phase 1 interventional study of KU-0059436 (AZD2281)(PARP inhibitor) and dacarbazine in Melanoma Neoplasms, sponsored by AstraZeneca. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-05-15.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing dacarbazine in Melanoma — none open to participants now, 1 under way, none of them phase 3. Dacarbazine · Melanoma.
Among the 30 studies testing dacarbazine in Melanoma, this one is the 16th largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2007, is one of 4 in phase 1, and was the 14th registered.
3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.
Browse Melanoma studies →None of the 30 studies testing dacarbazine in Melanoma is open now. The open studies under Melanoma, anywhere →
Dacarbazine: first FDA approval 1975 (DTIC-DOME). What it is approved for, and how studies give it, is on its page →
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 18 · Phase 3 6 · Phase 4 1
First in 1997; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is close to the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 64 across the 25 interventional studies. Of the 24 that completed or were terminated, 11 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 30 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
20 studies in Melanoma by AstraZeneca: 2 open now, 3 under way, none of them phase 3. Of 17 finished, 2 (12%) have results posted.
Among the 20 studies in Melanoma by AstraZeneca, this one is the 16th largest by enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2007, is one of 10 in phase 1, and was the 9th registered.
AstraZeneca’s Melanoma studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 30 studies testing dacarbazine in Melanoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 20 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase I, open-label, dose-escalating, study of the safety and tolerability of KU-0059436 in combination with DTIC in the treatment of patients with advanced melanoma who have not previously received systemic cytotoxic chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DTIC + KU-0059436
Drug: KU-0059436 (AZD2281)(PARP inhibitor) · Drug: dacarbazine
oral
Also known as: Olaparib
intravenous injection over at least 20 minutes
Also known as: DTIC
To determine the safety, tolerability, dose-limiting toxicity (DLT), and (MTD) of KU-0059436 in combination with dacarbazine.
Time frame: assessed every 3 weeks
Objective tumour response
Time frame: assessed every 6 weeks
The record gives a start of Jan 2007, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Olaparib · Dacarbazine